Allergan Chief Executive Officer David Pyott said in an interview with the Wall Street Journal he's looking at potential sizable acquisitions as he seeks to fend off a $53 billion hostile takeover offer from Valeant Pharmaceuticals and activist investor Bill Ackman. He said Allergan is considering both U.S. companies and companies located overseas, which could lead to a tax-cutting deal. Pyott said in the interview that Allergan's earnings results out later this month would reinforce his stance that the future value of the Botox-maker will exceed Valeant's offer price.

More from Video

China to Slash Automobile Tariffs and 4 Other Stories You Must Know Tuesday

China to Slash Automobile Tariffs and 4 Other Stories You Must Know Tuesday

Listen: Smart Technologies That Could Lure Millennials Back to Motorcycle Riding

Listen: Smart Technologies That Could Lure Millennials Back to Motorcycle Riding

60 Seconds: What is the Volcker Rule and How Does it Affect Your Portfolio?

60 Seconds: What is the Volcker Rule and How Does it Affect Your Portfolio?

Video: Here's How Global Stocks Can Boost Your Portfolio

Video: Here's How Global Stocks Can Boost Your Portfolio

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: When Planning for Retirement, Don't Underestimate Your Life Span